Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Transl Med ; 16(749): eadg9814, 2024 May 29.
Article in English | MEDLINE | ID: mdl-38809963

ABSTRACT

T cell-based cancer immunotherapy has typically relied on membrane-bound cytotoxicity enhancers such as chimeric antigen receptors expressed in autologous αß T cells. These approaches are limited by tonic signaling of synthetic constructs and costs associated with manufacturing. γδ T cells are an emerging alternative for cellular therapy, having innate antitumor activity, potent antibody-dependent cellular cytotoxicity, and minimal alloreactivity. We present an immunotherapeutic platform technology built around the innate properties of the Vγ9Vδ2 T cell, harnessing specific characteristics of this cell type and offering an allocompatible cellular therapy that recruits bystander immunity. We engineered γδ T cells to secrete synthetic tumor-targeting opsonins in the form of an scFv-Fc fusion protein and a mitogenic IL-15Rα-IL-15 fusion protein (stIL15). Using GD2 as a model antigen, we show that GD2-specific opsonin-secreting Vγ9Vδ2 T cells (stIL15-OPS-γδ T cells) have enhanced cytotoxicity and promote bystander activity of other lymphoid and myeloid cells. Secretion of stIL-15 abrogated the need for exogenous cytokine supplementation and further mediated activation of bystander natural killer cells. Compared with unmodified γδ T cells, stIL15-OPS-γδ T cells exhibited superior in vivo control of subcutaneous tumors and persistence in the blood. Moreover, stIL15-OPS-γδ T cells were efficacious against patient-derived osteosarcomas in animal models and in vitro, where efficacy could be boosted with the addition of zoledronic acid. Together, the data identify stIL15-OPS-γδ T cells as a candidate allogeneic cell therapy platform combining direct cytolysis with bystander activation to promote tumor control.


Subject(s)
Osteosarcoma , Receptors, Antigen, T-Cell, gamma-delta , Animals , Osteosarcoma/therapy , Osteosarcoma/immunology , Osteosarcoma/pathology , Humans , Receptors, Antigen, T-Cell, gamma-delta/metabolism , Receptors, Antigen, T-Cell, gamma-delta/immunology , Cell Line, Tumor , Cytotoxicity, Immunologic , Mice , T-Lymphocytes/immunology , Zoledronic Acid/pharmacology , Bystander Effect , Interleukin-15 , Cell Engineering
2.
J Cell Biol ; 220(6)2021 06 07.
Article in English | MEDLINE | ID: mdl-33914026

ABSTRACT

Rac1 GTPase is hyperactivated in tumors and contributes to malignancy. Rac1 disruption of junctions requires its effector PAK1, but the precise mechanisms are unknown. Here, we show that E-cadherin is internalized via micropinocytosis in a PAK1-dependent manner without catenin dissociation and degradation. In addition to internalization, PAK1 regulates E-cadherin transport by fine-tuning Rab small GTPase function. PAK1 phosphorylates a core Rab regulator, RabGDIß, but not RabGDIα. Phosphorylated RabGDIß preferentially associates with Rab5 and Rab11, which is predicted to promote Rab retrieval from membranes. Consistent with this hypothesis, Rab11 is activated by Rac1, and inhibition of Rab11 function partially rescues E-cadherin destabilization. Thus, Rac1 activation reduces surface cadherin levels as a net result of higher bulk flow of membrane uptake that counteracts Rab11-dependent E-cadherin delivery to junctions (recycling and/or exocytosis). This unique small GTPase crosstalk has an impact on Rac1 and PAK1 regulation of membrane remodeling during epithelial dedifferentiation, adhesion, and motility.


Subject(s)
Adherens Junctions/physiology , Exocytosis , Keratinocytes/physiology , p21-Activated Kinases/metabolism , rab GTP-Binding Proteins/metabolism , rac1 GTP-Binding Protein/metabolism , Actins/metabolism , Adherens Junctions/chemistry , Cells, Cultured , Humans , Keratinocytes/cytology , Signal Transduction , p21-Activated Kinases/genetics , rab GTP-Binding Proteins/genetics , rac1 GTP-Binding Protein/genetics
3.
Elife ; 82019 12 03.
Article in English | MEDLINE | ID: mdl-31793877

ABSTRACT

Stable cell-cell contacts underpin tissue architecture and organization. Quantification of junctions of mammalian epithelia requires laborious manual measurements that are a major roadblock for mechanistic studies. We designed Junction Mapper as an open access, semi-automated software that defines the status of adhesiveness via the simultaneous measurement of pre-defined parameters at cell-cell contacts. It identifies contacting interfaces and corners with minimal user input and quantifies length, area and intensity of junction markers. Its ability to measure fragmented junctions is unique. Importantly, junctions that considerably deviate from the contiguous staining and straight contact phenotype seen in epithelia are also successfully quantified (i.e. cardiomyocytes or endothelia). Distinct phenotypes of junction disruption can be clearly differentiated among various oncogenes, depletion of actin regulators or stimulation with other agents. Junction Mapper is thus a powerful, unbiased and highly applicable software for profiling cell-cell adhesion phenotypes and facilitate studies on junction dynamics in health and disease.


Subject(s)
Cell Communication/physiology , Computational Biology/methods , Endothelial Cells/physiology , Intercellular Junctions/physiology , Keratinocytes/physiology , Myocytes, Cardiac/physiology , Animals , Cadherins/metabolism , Cell Adhesion/physiology , Cells, Cultured , Endothelial Cells/metabolism , Humans , Intercellular Junctions/metabolism , Keratinocytes/metabolism , Microscopy, Confocal , Myocytes, Cardiac/metabolism , Phenotype , Rats, Sprague-Dawley , Software
SELECTION OF CITATIONS
SEARCH DETAIL
...